Method for generating influenza viruses and vaccines
AssigneeSt. Jude Children's Research Hospital
InventorsRobert Gordon Webster, Richard John Webby, Hiroichi Ozaki
Life of this patent
Estimating the term…
Abstract
The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain with the NS gene of the A/England/1/53 strain. The invention provides influenza viruses and vaccines generated in mammalian cells as well as methods for producing such. The invention further provides an influenza virus master strain and kits for generating reassortant influenza viruses in mammalian cell culture and methods of making and using the master strain.
Claims16
A method for producing a reassortant influenza virus comprising transfecting host cells with expression plasmids containing PB2, PB1, PA, NP and M genes from A/PuertoRico/8/34 influenza strain, an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6, and HA and NA genes from an influenza virus of interest other than A/England/1/53, to obtain a reassortant influenza virus.
A reassortant influenza virus strain comprising a modified A/PuertoRico/8/34 influenza strain, wherein an NS gene of the A/PuertoRico/8/34 influenza strain is replaced with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6, and HA and NA genes from an influenza virus strain of interest other than A/England/1/53.
A method of producing a reassortant influenza virus vaccine comprising transfecting cells with expression plasmids containing the PB2, PB1, PA, NP and M genes from an A/PuertoRico/8/34 influenza strain, an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6, and HA and NA genes from an influenza virus of interest other than A/England/1/53, to obtain a reassortant influenza virus vaccine.
A reassortant influenza virus vaccine comprising a modified A/PuertoRico/8/34 influenza strain and a pharmaceutically acceptable carrier, wherein an NS gene of the A/PuertoRico/8/34 influenza strain is replaced with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6, and HA and NA genes from an influenza virus strain of interest other than A/England/1/53.
The vaccine of claim 15, further comprising an adjuvant which enhances an influenza virus immune response.
A kit for producing an influenza virus master strain comprising expression plasmids containing PB2, PB1, PA, NP and M genes from an A/PuertoRico/8/34 influenza strain and an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6.
A modified A/PuertoRico/8/34 influenza virus master strain, wherein PB2, PB1, PA, NP and M genes are from A/PuertoRico/8/34 influenza strain, a NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:5 and an NS2 protein having an amino acid sequence comprising SEQ ID NO:6, and HA and NA genes are from any influenza virus other than A/England/1/53.
An A/PuertoRico/8/34 master strain used for producing an influenza virus, the improvement which consists of replacing an NS gene of the A/PuertoRico/8/34 influenza strain with an NS gene encoding an NS1 protein having an amino acid sequence comprising SEO ID NO:5 and an NS2 protein having an amino acid sequence comprising SEO ID NO:6, and HA and NA genes from any influenza virus other than A/England/1/53.
A method for producing a reassortant influenza virus comprising transfecting host cells with expression plasmids containing PB2, PB1, PA, NP and M genes from A/PuertoRico/8/34 influenza strain, HA and NA genes from an influenza virus of interest other than A/England/1/53, and an NS gene encoding an NS1 protein having an amino acid sequence comprising SEQ ID NO:3 with one or more changes selected from the group consisting of amino acid substitutions at positions 21, 58, 60, 127, 174, and 189 and a deletion of amino acids 231–238 and encoding an NS2 protein having an amino acid sequence comprising SEQ ID NO:4 with one or more changes selected from the group consisting of amino acid substitutions at positions 16, 31, 86, and 107 to obtain a reassortant influenza virus.
Dependencies are inferred from the claim text.